UBS Group’s Defiance Nasdaq Junior Biotechnology ETF IBBJ Stock Holding History

UBS Group’s Portfolio IBBJ Stock Details IBBJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-400	Closed	-$12K	–	11311
2021 Q3	$12K	Sell	400 -633	-61%	-$19.3K	﹤0.01%	7845
2021 Q2	$34K	Buy	1,033 +47	+5%	+$1.49K	﹤0.01%	6821
2021 Q1	$33K	Buy	+986	New	+$35.8K	﹤0.01%	6943
2020 Q4	–	Sell	-924	Closed	-$24K	–	8993
2020 Q3	$24K	Buy	+924	New	+$23.2K	﹤0.01%	6180

UBS Group's IBBJ Position: Q4 2021 in Review

UBS Group sold out of Defiance Nasdaq Junior Biotechnology ETF (IBBJ) in Q4 2021, closing a stake of 400 shares — an estimated $12K sold.

UBS Group first reported a position in IBBJ in Q3 2020 and held it in 4 quarters. The position peaked at $34K in Q2 2021. 0 funds tracked by Wall St. Rank hold IBBJ as of Q4 2021.

UBS Group reported no remaining Defiance Nasdaq Junior Biotechnology ETF position as of Q4 2021 after selling out during the quarter.
UBS Group sold 400 Defiance Nasdaq Junior Biotechnology ETF shares in Q4 2021, an estimated $12K.
UBS Group first reported a position in Defiance Nasdaq Junior Biotechnology ETF in Q3 2020 and held it in 4 quarters.
UBS Group's Defiance Nasdaq Junior Biotechnology ETF position peaked at $34K in Q2 2021.
0 funds tracked by Wall St. Rank held Defiance Nasdaq Junior Biotechnology ETF as of Q4 2021.

Based on UBS Group's 13F filing for Q4 2021, filed 14 Feb 2022.